ARLINGTON, Va. – The Digital Therapeutics Alliance has released a whitepaper that seeks to define digital therapeutics (DTx), create industry best practices and share examples of DTx products currently on the market or under development.
In the paper, the group defines digital health as “all technologies that engage patients for health-related purpose,” then explains that DTx products “form an independent category of evidence-based products within the broader digital health landscape.” DTx products are distinguished from other digital health categories through their primary function of delivering software-generated therapeutic interventions directly to patients to prevent, manage or treat a medical disorder or disease, the paper’s authors wrote.
The authors of the paper wrote that the benefits of DTx products include: delivering reliable, evidenced-based interventions with a high control of quality; increasing access to therapies that are clinically demonstrated as safe and effective; and personalizing care based on individual patients’ needs and abilities.
Following the release of the whitepaper, the DTA plans to continue developing best practices and frameworks around digital therapeutics.
“The growth of the digital therapeutic industry will be dramatic over the next 18 months, resulting in major impacts for users, organizations and the health care industry,” wrote the authors. “The integration of digital therapeutics into health care is no longer a theoretical conversation.” DTA launched in October 2017 through a collaboration of four digital therapeutics companies—Akili Interactive, Propeller Health, Voluntis and WellDoc—with the mission of broadening the understanding, adoption and integration of clinically-validated digital therapeutics into healthcare through education, advocacy and research.